Silmitasertib (CX-4945) in Patients With Severe Coronavirus Disease 2019 (COVID-19)
Status:
Recruiting
Trial end date:
2021-09-30
Target enrollment:
Participant gender:
Summary
This multi-center, open-label, 2 arm parallel-group, randomized, interventional prospective
exploratory study in 40 patients aimed to evaluate safety and explore putative clinical
benefits of Silmitasertib 1000 mg BID dose in patients with severe illness caused be
SARS-COV-2. This will be a two-arm trial comparing the SOC/best supportive care alone to the
SOC/best supportive care with addition of Silmitasertib (allocation ratio 1:1).